Commercially launch the Omnipod 5 system
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 4 Nov 2020
- Due
- 30 Jun 2021
- Checked
- 10 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“on track for planned commercial launch in the first half of 2021”
What we found
Evidence strength A What the grades mean
The August 2021 10-Q said the FDA review was taking longer than expected and the limited launch was moved to the second half of 2021, late Q4.
-
A Insulet Corporation 10-Q filed 2021-08-06
“This review is taking longer than we had anticipated. We now expect to receive FDA clearance and launch our limited commercial release in the second half of the year, most likely late in the fourth quarter.” ✓ confirmed on the page
-
A Insulet Corporation 10-Q filed 2021-11-05
“As previously reported in our Form 10-Q for the quarter ended June 30, 2021, we expect to receive FDA clearance and launch our limited commercial release late in the fourth quarter.” ✓ confirmed on the page
Market reaction: the shares moved +5.4% against the S&P 500 over the three sessions around the disclosure (4 Nov 2021 to 9 Nov 2021). What this measures
Checked 10 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +730 days
- 2 versions
-
Version 1 · original · stated 4 Nov 2020
Deadline 30 Jun 2021 (“in the first half of 2021”) · wording expected
-
Version 2 · stated 4 May 2023
Deadline 30 Jun 2023 (“mid-year”) · wording firm
“On track to commercially launch Omnipod 5 in the United Kingdom mid-year”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Commercial launch
- Indicative materiality
- Medium rules
- Action
- Commercially
- Deliverable
- Omnipod 5 commercial launch
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Insulet Corporation? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2020-PODD-006275 · Corrections policy